Repurposing apoptosis-inducing cancer drugs to treat schistosomiasis

Future Medicinal Chemistry

Volumn 7, Issue 6, 2015, Pages 707-711

  Lee, Erinna F ^a,b   Fairlie, Walter Douglas ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

apoptosis; Bcl 2; BH3 mimetic; cancer drugs; kinase inhibitors; praziquantel; schistosomiasis; small molecule inhibitor

Indexed keywords

APOPTOSIS INDUCING FACTOR; BH3 PROTEIN; ENZYME; HISTONE; HISTONE MODIFYING ENZYME; PROTEIN KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTISCHISTOSOMAL AGENT; HELMINTH PROTEIN; PROTEIN BCL 2; PROTEIN KINASE INHIBITOR;

APOPTOSIS; DRUG REPOSITIONING; GENOME; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PARASITOLOGY; PROCEDURES; PROTEIN TERTIARY STRUCTURE; SCHISTOSOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG REPOSITIONING; HELMINTH PROTEINS; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2; SCHISTOSOMA; SCHISTOSOMIASIS; SCHISTOSOMICIDES;

EID: 84929731216     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.164     Document Type: Note

References (20)

1. Greenberg RM. New approaches for understanding mechanisms of drug resistance in schistosomes. Parasitology 140(12), 1534-1546 (2013).
2. Berriman M, Haas BJ, LoVerde PT et al. The genome of the blood fluke Schistosoma mansoni. Nature 460(7253), 352-358 (2009).
3. Schistosoma japonicum Genome S, Functional Analysis C. The Schistosoma japonicum genome reveals features of hostparasite interplay. Nature 460(7253), 345-351 (2009).
4. Young ND, Jex AR, Li B et al. Whole-genome sequence of Schistosoma haematobium. Nat. Genet. 44(2), 221-225 (2012).
5. Dissous C, Grevelding CG. Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective? Trends Parasitol. 27(2), 59-66 (2011).
6. Lee EF, Clarke OB, Evangelista M et al. Discovery and molecular characterization of a Bcl-2-regulated cell death pathway in schistosomes. Proc. Natl Acad. Sci. USA 108(17), 6999-7003 (2011).
7. Lee EF, Young ND, Lim NT, Gasser RB, Fairlie WD. Apoptosis in schistosomes: toward novel targets for the treatment of schistosomiasis. Trends Parasitol. 30(2), 75-84 (2014).
8. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell. Biol. 15(1), 49-63 (2014).
9. Roy MJ, Vom A, Czabotar PE, Lessene G. Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway. Br. J. Pharmacol. 171(8), 1973-1987 (2014).
10. Han H, Peng J, Gobert GN et al. Apoptosis phenomenon in the schistosomulum and adult worm life cycle stages of Schistosoma japonicum. Parasitol. Int. 62(2), 100-108 (2013).
11. Galanti SE, Huang SC, Pearce EJ. Cell death and reproductive regression in female Schistosoma mansoni. PLoS Negl. Trop. Dis. 6(2), e1509 (2012).
12. Hines-Kay J, Cupit PM, Sanchez MC, Rosenberg GH, Hanelt B, Cunningham C. Transcriptional analysis of Schistosoma mansoni treated with praziquantel in vitro. Mol. Biochem. Parasitol. 186(2), 87-94 (2012).
13. Peng J, Gobert GN, Hong Y et al. Apoptosis governs the elimination of Schistosoma japonicum from the non-permissive host Microtus fortis. PLoS ONE 6(6), e21109 (2011).
14. Pierce RJ, Dubois-Abdesselem F, Caby S et al. Chromatin regulation in schistosomes and histone modifying enzymes as drug targets. Mem. Inst. Oswaldo Cruz 106(7), 794-801 (2011).
15. Beckmann S, Grevelding CG. Imatinib has a fatal impact on morphology, pairing stability and survival of adult Schistosoma mansoni in vitro. Int. J. Parasitol. 40(5), 521-526 (2010).
16. Beckmann S, Leutner S, Gouignard N, Dissous C, Grevelding CG. Protein kinases as potential targets for novel anti-schistosomal strategies. Curr. Pharm. Des. 18(24), 3579-3594 (2012).
17. Vanderstraete M, Gouignard N, Cailliau K et al. Dual targeting of insulin and venus kinase Receptors of Schistosoma mansoni for novel anti-schistosome therapy. PLoS Negl. Trop. Dis. 7(5), e2226 (2013).
18. Dubois F, Caby S, Oger F et al. Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. Mol. Biochem. Parasitol. 168(1), 7-15 (2009).
19. Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature 448(7154), 645-646 (2007).
20. Eissa MM, El-Azzouni MZ, Amer EI, Baddour NM. Miltefosine, a promising novel agent for schistosomiasis mansoni. Int. J. Parasitol. 41(2), 235-242 (2011).